Company Filing History:
8 out of 13 
3 out of 7 
3 out of 3 
Years Active: 2017-2025
Title: Innovations by Yanxin Liu: Pioneering TRK Kinase Inhibitors
Introduction
Yanxin Liu, an accomplished inventor based in Chongqing, China, has made significant contributions to pharmaceutical science through his innovative research and development. With a total of 11 patents to his name, Liu has focused primarily on developing compounds that address critical health issues.
Latest Patents
Among his latest innovations are the "Macrocyclic Compounds as TRK Kinase Inhibitors," which includes specific TRK inhibitors, their pharmaceutical compositions, and methods of utilization. This patent is pivotal, offering potential therapeutic solutions for various types of cancers. Another notable patent is for "Apoptosis-Inducing Agents," which encompasses Bcl-2 inhibitors, their pharmaceutical compositions, and methods of use, showcasing his commitment to advancing cancer treatments.
Career Highlights
Yanxin Liu has held key positions in notable companies, including Shanghai Fochon Pharmaceutical Co., Ltd. and Chongqing Fochon Pharmaceutical Co., Ltd., where he has played a crucial role in drug development and innovation. His work has not only garnered recognition locally but also laid the groundwork for global advancements in therapeutic solutions.
Collaborations
Throughout his career, Liu has collaborated with esteemed colleagues such as Xingdong Zhao and Weibo Wang, collectively fostering an environment of innovation and shared knowledge within the pharmaceutical community. These collaborations have significantly contributed to the success of his research endeavors.
Conclusion
With a robust portfolio of patents and a dedication to advancing pharmaceutical sciences, Yanxin Liu continues to be a driving force in the field of cancer treatment innovations. His efforts not only highlight his individual brilliance but also the collaborative spirit that propels research forward, holding promise for future breakthroughs in healthcare.